Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial Health rating, has positioned itself as an innovative player in the ...

Monoclonal antibody (mAb) therapy involves making large amounts of antibodies that recognize antigens that are usually found on the surface of cancer cells. They are then injected into the body ...

About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

The SADA technology was developed at Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs. Presentation of significant preclinical and translational pharmacokinetics data ...

AbbVie is looking at combining lemzoparlimab with its blood cancer therapy Venclexta (venetoclax) in clinical trials. According to I-Mab, its antibody has a lower tendency than other anti-CD47 ...

Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote.